A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

Trial Details

NCT ID
NCT06999187
Phase
PHASE1
Sponsor
Dren Bio
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Locations (sample)
  • Denver, Colorado, United States|39.73915,-104.9847
  • Orlando, Florida, United States|28.53834,-81.37924
  • Sarasota, Florida, United States|27.33643,-82.53065
  • Huntersville, North Carolina, United States|35.41069,-80.84285
  • Oklahoma City, Oklahoma, United States|35.46756,-97.51643

Key Eligibility Criteria

  • Histologically confirmed epithelial cancer of the following tumor types: breast (TNBC, HR+/HER2-/+BC), NSCLC, cervical, CRPC, PDAC, HNSCC, endometr…
  • Relapsed or refractory with at least 2 prior lines of therapy and for which no standard of care treatment options are available
  • Radiographically measurable disease
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →